5C-D, also known as 4-methyl-2,5-dimethoxy-α-propylphenethylamine, is a putatively non-hallucinogenic serotonin 5-HT2 receptor agonist of the phenethylamine and α-propylphenethylamine families related to the 4C drug Ariadne (4C-D).
At the serotonin 5-HT2A receptor, 5C-D is a potent and higher-efficacy partial agonist, with an of 291nM and an of 69%. It is about half as potent as Ariadne as a serotonin 5-HT2A receptor agonist and has about 15% lower efficacy in activating the receptor in comparison. 5C-D has also been shown to be a serotonin 5-HT2B receptor agonist. In contrast to Ariadne and serotonergic psychedelics, 5C-D does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.
5C-D was first described in the scientific literature by Michael Cunningham and colleagues by 2023. It was synthesized and assessed during structure–activity relationship (SAR) studies of Ariadne.
See also Substituted methoxyphenethylamine Non-hallucinogenic 5-HT2A receptor agonist 4C and Ariadne (4C-D) α-Propylmescaline (APM)
References
External links 5C-D - Isomer Design